Skip to main content

icatibant acetate (Firazyr®)

 

Following a limited submission

AWMSG advice

Status: Recommended

Icatibant acetate (Firazyr®) is recommended as an option for use within NHS Wales for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor deficiency.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

 Final Recommendation: icatibant acetate (Firazyr) 3293 (PDF, 306Kb)
 Appraisal Report: icatibant acetate (Firazyr) 3293 (PDF, 224Kb)

Medicine details

Medicine name icatibant acetate (Firazyr®)
Formulation 30 mg solution for injection
Reference number 3293
Indication

Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor deficiency

Company Shire Pharmaceuticals
BNF chapter Respiratory system
Submission type Limited
Status Recommended
Advice number 0818
NMG meeting date 11/04/2018
AWMSG meeting date 23/05/2018
Date of issue 12/06/2018
Date of last review December 2021
Commercial arrangement WPAS
Follow AWTTC: